LEVITRA

Administration of LEVITRA with nitrates and nitric oxide donors is contraindicated. Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors, including LEVITRA, may potentiate the hypotensive effects of nitrates

...continue reading

LEVITRA: Most Common Side Effects

The most frequently occurring side effects (≥2% with LEVITRA, and more frequent than placebo) include "scrollbars=yes, resizable=yes, width=400, height=400,top=100, left=100"[1]:

In fixed- and flexible-dose,|| randomized, controlled trials of 5-mg, 10-mg, or 20-mg doses of vardenafil. LEVITRA
n=2203
Placebo
n=1199
Headache 15% 4%
Flushing 11% 1%
Rhinitis 9% 3%
Dyspepsia 4% 1%
Accidental Injury 3% 2%
Sinusitis 3% 1%
Flu Syndrome 3% 2%
Dizziness 2% 1%
Increased Creatine Kinase 2% 1%
Nausea 2% 1%
|| Flexible-dose studies started all patients at LEVITRA 10 mg and allowed decrease in dose to 5 mg or increase in dose to 20 mg based on side effects and efficacy. "scrollbars=yes, resizable=yes, width=400, height=400,top=100, left=100"[1]
All the events listed in this table were deemed to be adverse drug reactions with the exception of accidental injury.

Please see complete Prescribing Information, including Patient Information Leaflet, by clicking the ["Prescribing Information"] navigation above.